Genocea commercializes key breakthroughs in vaccine discovery and development. The company was founded by Lux and spun-out from Harvard Medical School. The company completed its IPO in 2014.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases. Traditional discovery methods have proven unable to identify the targets of immune response. ATLAS, Genocea's proprietary technology platform, mimics the human immune system to identify the targets most likely to illicit an immune response. Genocea's pipeline of novel, clinical-stage, T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for pneumococcus, and earlier-stage programs in chlamydia, malaria and cancer immunotherapy.
-
Industry
-
Milestones
- Lux founded: 2006
- IPO (NASDAQ: GNCA) 2014
-
Founders
- Kevin Bitterman
- Darren Higgins
- Robert Paull
- David Sinclair
- Larry Bock
LUX Partners
-
Latest Tweets
- #DidYouKnow @GenoceaBio's ATLAS™ platform identifies neoantigens based on individual immune responses and selects t… https://t.co/nVJah9TyhP
- #ICYMI – last week, @GenoceaBio shared preliminary findings hinting that GEN-009, our neoantigen vaccine, may provi… https://t.co/hbHXco0B5H
- Happening now, Dr. Maura Gillison of @MDAndersonNews joins us to share encouraging results from Part B of our ongoi… https://t.co/J0GQoawD6T
